This mechanism has shown potential in treating certain highly immunogenic tumors, empowering the immune system to respond more effectively against cancer.32,33 Limited research has been conducted on adaptive NK therapy for HCC, in which a partial response of 18% has been shown34 In this study, we investigated a combination therapy of activated NK cells pre-treated with anti-NKG2A, an NKG2A blocker, to evaluate its safety in HCC patients. This evidence concerns the gene KLRC1 and cancer.